is...retired
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
thanks missed it
you are to me like the ant to the elephant.
I think the SH pr covers it
what happened to that term deal?
my email didn't bounce. went thru but no response from the Soros wanna be.
thank you
did IPIX extend or renew lease on headquarters.
Emailed IPIX with my usual question. Tested both Invester Relation email contacts. They are kaput.
nope . Gist the same wording slightly different. It was my description of the answer that caused quite a stir.
I sent the following:
I hope it is permissible to tell us if you signed a lease for the location you have used the last couple of years.
if you answer can i have permission to post on iHUB
yes. 3 friends 800k each not too long ago
I emailed IPIX again asking if they have signed a new lease yet. Also asked permission to post their response if any.
email has not been returned as undeliverable.
IPIX is still showing at that Calgene thing
IPIX is still involved with term something or other paper (deal)
IPIX is/was negotiating for extend/renewal of office/lab space
I agree with the no nos Leo is a pee poor communicator.
IPIX is still showing at that Calgene thing
IPIX is still involved with term something or other paper (deal)
IPIX is/was negotiating for extend/renewal of office/lab space
I agree with the no nos Leo is a pee poor communicator.
I just emailed IPIX again asking permission to post email response to me. The first item.
well i think Karin posted that the lease was renewed. Then later she said she may have misspoken.
That is why I posted about the lease being renewed.
Later I posted about the email from LE to me . I paraphrased and gave my interpretation.
SOOOO I don't know for sure the lease was renewed .
I never said there was language in the filing that the lease was renewed. Someone else did and I took it as a fact.
Although ordered to provide a quote for the language I provided I decline.
Our Ihub site still provides the long term contact info. Take it up with them.
no he didn't tell me that in an email. paraphrasing email he told me they were in negotiations to stay.
that is my interpretation and any reasonable person's interpretation.
That term deal or whatever it's called was signed in June or before. That is plenty of time for it to come apart or be rejected. Since that would be a material event LE would have to tell us. This is looking better all the time.
could it be evonik?
I use the email on this site. info@harmic.com
I think there is a chance some good news is coming. Bad news was June. Aspire threw them a lifesaver.
Leo (imo) never knows when to quit but maybe others more realistic will prevail.
Waiting to hear from Cabel and LilbK
I emailed asking for one. Urge others to do the same keeping it polite.
Don't you think LE owes the SH an update on what's going on now since we know what was happening last June. We still have sept 30 ahead of us.
At least he gave us a hint since the lease is renewed.
Let's hope he doesn't screw up the deal and gets it done quickly.
He and Menon could have paid the CRO off . They must have had a good idea how the test for P was going. Something fishy here.
Today LE Today!
I'm waiting to hear from you cabel.
Gov
said the spider to the fly
I think there is some news in the 10K that is very positive. It has been hinted at. This my opinion not investment advice.
Innovation Pharmaceuticals to Present Brilacidin for Inflammatory Bowel Disease at Inaugural “IBD Innovate 2018” Conference Hosted by the Crohn’s & Colitis Foundation
Email Print Friendly Share
September 05, 2018 09:00 ET | Source: Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today that the Company has been invited to present on the planned continued development of Brilacidin for Inflammatory Bowel Disease at the inaugural “IBD Innovate 2018” conference.
The day-long conference, hosted by the Crohn’s & Colitis Foundation and sponsored, in part, by Celgene Corporation, will be held on November 13, 2018, at the New York Academy of Medicine located in New York, NY. Participants will include diverse stakeholders interested in scientific advances and innovative programs in IBD, toward accelerating the introduction of novel products to address unmet medical needs in the treatment of chronic bowel diseases. Additional conference details can be found on the Crohn’s & Colitis Foundation website, or by clicking here.
The scientific poster—titled “Brilacidin for Inflammatory Bowel Disease: A Novel, Non-Corticosteroid, Non-Biologic Drug Candidate in Clinical Development”—to be presented at the conference will be available in the Events and Presentations section of the Company website on November 13, 2018.
“As an academic clinical investigator and practicing gastroenterologist, I believe that Brilacidin is an extremely promising mid-phase IBD drug candidate, particularly once formulated for oral delivery,” commented Francis A. Farraye, MD, MSc, Clinical Director, Section of Gastroenterology at Boston Medical Center, Professor of Medicine at Boston University School of Medicine and Scientific Advisor to Innovation Pharmaceuticals. “Brilacidin’s unique and broad mechanism-of-action—antibacterial and anti-inflammatory—is a potent combination, as infection and inflammation are both implicated in IBD pathogenesis and progression.”
About Brilacidin for IBD
Brilacidin is being developed as a novel, non-corticosteroid, non-biologic treatment, with formulation development plans including oral tablets for the treatment of Ulcerative Colitis and Crohn’s Disease, and foam and/or gel for the treatment of mild-to-moderate Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of IBD. As released previously, a majority of patients treated with Brilacidin administered via retention enema achieved Clinical Remission in a Phase 2, open-label, Proof-of-Concept (PoC) clinical trial evaluating Brilacidin for UP/UPS.
About Brilacidin
Brilacidin is Innovation Pharmaceuticals’ lead drug candidate in its defensin mimetic franchise. Modeled after Host Defense Proteins (HDPs), the “front-line” of defense in the immune system, it is a small, non-peptidic, synthetic molecule that kills pathogens swiftly and thoroughly. Just as importantly, Brilacidin also functions in a robust immunomodulatory capacity, lessening inflammation and promoting healing. Due to its unique properties, the Company has studied Brilacidin’s effect on Oral Mucositis (under Fast Track designation) and on Ulcerative Proctitis/Proctosigmoiditis (UP/UPS) in Phase 2 trials. Additional trials of Brilacidin are planned in other conditions, including: Atopic Dermatitis and Acne. Brilacidin is also being developed under FDA’s Qualified Infectious Disease Product (QIDP) designation as an antibacterial product for Acute Bacterial Skin and Skin Structure Infection (ABSSSI)—qualifying it for Fast Track and possible Priority FDA Review and a potential extra 5 years of United States market exclusivity upon drug approval.
Learn more here:
http://www.ipharminc.com/brilacidin-1
Alerts
Sign-up for Innovation Pharmaceuticals email alerts is available at:
http://www.ipharminc.com/email-alerts/
About Innovation Pharmaceuticals
Innovation Pharmaceuticals Inc. (IPIX) is a clinical stage biopharmaceutical company developing a world-class portfolio of innovative therapies addressing multiple areas of unmet medical need, including inflammatory diseases, cancer, infectious disease, and dermatologic diseases. Brilacidin, a versatile compound with broad therapeutic potential, is in a new chemical class called defensin-mimetics. A Phase 2 trial of Brilacidin as an oral rinse for the prevention of Severe Oral Mucositis (SOM) in patients with Head and Neck Cancer, met its primary and secondary endpoints, including reducing the incidence of SOM. Positive results were also observed in a Phase 2 Proof-of-Concept trial treating patients locally with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis. A Phase 2b trial of Brilacidin showed a single intravenous dose of the drug delivered comparable outcomes to a seven-day dosing regimen of the FDA-approved blockbuster daptomycin in treating Acute Bacterial Skin and Skin Structure Infections. Kevetrin is a novel anti-cancer drug shown to modulate p53, often referred to as the “Guardian Angel Gene” due to its crucial role in controlling cell mutations, and has successfully completed a Phase 2 trial in ovarian cancer. Prurisol, an oral psoriasis drug candidate acting through immune modulation and PRINS reduction, has now completed a Phase 2b trial and is awaiting statistical analysis. More information is available on the Company website at www.IPharmInc.com.
Forward-Looking Statements: This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 including statements concerning projected timelines for the initiation and completion of clinical trials, our future drug development plans, other statements regarding future product developments, including with respect to specific indications, and any other statements which are other than statements of historical fact. These statements involve risks, uncertainties and assumptions that could cause the Company’s actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. The Company has in some cases identified forward-looking statements by using words such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “plans,” “intends,” “goal,” “potential,” “may,” “suggest,” and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are the Company’s need for, and the availability of, substantial capital in the future to fund its operations and research and development; including the amount and timing of the sale of shares of common stock to Aspire Capital; the fact that the Company’s compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in the Company’s filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. The Company undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
INVESTOR AND MEDIA CONTACT
Innovation Pharmaceuticals Inc.
Leo Ehrlich
info@ipharminc.com
Related Articles
More articles issued by Innovation Pharmaceuticals, Inc.
More articles related to:
Company Announcement
Profile
Innovation Pharmaceuticals, Inc.
Subscribe via RSS
Subscribe via ATOM
Javascript
Beverly, Massachusetts, UNITED STATES
http://www.cellceutix.com
There you are. I fell better now.
Cabel i sent an email asking for info. How about you and Karin trying.
I asked if IPIX renewed or extended the lease and I requested permission to post reply.
I am not authorized to open this
Innovation Pharmaceuticals Inc. (Form: 8-K, Received: 06/29/2018 ...
https://www.otcmarkets.com/filing/rtf?id=12839447&guid=lwUEU61SCPQwkth
o Pre-commencement communications pursuant to Rule 14d-2(b) under the ... of the FDA's granting of the Company's request for Breakthrough Therapy Designation for the Company's Brilacidin compound in the indication of Oral Mucositis; ...... The Company shall promptly secure the listing of all of the Purchase Shares, ...
What is the latest from those who live near office in beverly? TIA
Just heard on Fox news Trump okayed reducing regulations for new drug approval and faster generic drugs.
this person left IPIX employment in January 2018. Does this mean request for FDA BTD was sent in in January 2018?
? Study Manager, responsible for oversight of operational study deliverables, and day-to- day study operations and administration.
? Assisted with creation & presentations of materials for SIVs
? Assisted with preparation and made input to Investigator Brochure, Clinical Protocols, Informed Consents, manuals and forms needed for clinical trials
? Handled contract negotiation of vendors for clinical supplies for trials as well as hotel & travel vendors for potential investigator meetings; also reviewed & approved trial invoicing; vendor management
? Responsible for overall IRB submissions for oral mucositis study with central IRB
? Made site visits as part of the team conducting SIVs, also made follow up visits to sites
(both trials)
? Over-saw roll out of ClinTrialApp for Oral Mucositis study; responsible for updating documents & other information in app
? Acted at TMF Process Owner assisting w/ resourcing, unitization and oversight of the Trial Master File system; also supervised Clinical Trial Associates (TMF Specialists) responsible for TMF, maintenance & reorganization of Beverly locked file room
? Organized, ordered, stored and tracked expenditures of clinical supplies for Oral
Mucositis trial; oversaw consultant responsible for shipping clinical supplies
? Assisted with preparation of electronic documents for FDA submissions (for several INDs & study serial submission) including fact checking, proofreading, reformatting, etc. utilizing MS Word and Adobe Acrobat.
? Assist with compiling hybrid paper/electronic submissions to FDA including preparing desk copies (as needed) & shipping to FDA; also burned & tested CDs for submissions
? Responsible creating and maintaining for all submission documents (1571, cover letters, etc.), preparation of submissions, shipping and filing of paper copies in Beverly.
? Assisted with compilation, preparation of & submission of IND for Oral Mucositis
that answered my question
Did LE say in the latest Newsletter citing the 3 steps that the stock had to be at .50 for aspire to act? If so is that why the stock is resisting the gloom and doomers so well?
I remember when K was on cohort 4 or 5 and Dana Farber was shuffling technicians around. We had an expert on P53 lined up tp do the work. Things got delayed. Leo and dana farmer fudged around and then i found the experts obituary in the newspaper.
I don't know why I remembered that just now.
I think they are counting on Part 3 of that email to investors.
#1 BTD
#2 P results
#3 Contract for millions
_______________________________-
email to me. not looking to close up shop (my interpretation)